A61P 5 - Drugs for disorders of the endocrine system

Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
10/2002
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443568A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443567A1 Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereofas tocolytic oxytocin receptor antagonists
10/24/2002	CA2443566A1 Novel 10-cyclohexenyl-phenyl pyrrolobenzodiazepine-3-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443565A1 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
10/24/2002	CA2443564A1 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/23/2002	WO2001095940A1 Sustained release compositions
10/23/2002	EP1250432A2 Nuclear hormone receptors
10/23/2002	EP1250328A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
10/23/2002	EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002	EP1250148A1 Use of fsh for treating infertility
10/23/2002	EP1250146A2 Use of neurotoxins for treating diabetes
10/23/2002	EP1250139A1 Product for treating gynecomastia
10/23/2002	EP1250138A1 Fulvestrant formulation
10/23/2002	CN1376166A Peptide that lower blood glucose levels
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376070A Method for the therapeutic management of extrauterine prolifieration of endometrical tissue, chronic pelvic pain and fallopian tube obstruction
10/23/2002	CN1376069A Methods and compositions for reducing sympathomimetic-induced side effects
10/23/2002	CN1376062A Use of amino acids for making medicine for treating to insulin-resistance
10/23/2002	CN1375490A Novel indeno indolone compound, its preparation method and drug composition comprising the same
10/23/2002	CN1375312A Goiter and hyperthyroidism treating ointment
10/23/2002	CN1093130C Substituted pyrido 6,6-bicyclic derivatives
10/23/2002	CA2407472A1 Sustained release compositions
10/22/2002	US6469166 Crf receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders
10/22/2002	US6469047 Tyrosine derivatives
10/22/2002	US6469021 Non-peptide antagonists of GLP-1 receptor and methods of use
10/22/2002	US6469007 P-substituted-n-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-n-pyridin-2-yl-benzamide,
10/22/2002	US6468975 Glucocorticoid receptor antagonists that are preferably liver selective and are useful in treatment of diabetes
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468737 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
10/22/2002	CA2022437C Reduced size lhrh analogs
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081444A1 1-indolyl derivatives, use thereof for production of medicaments, a method for production of said 1-indolyl derivatives and pharmaceutical preparations containing 1-indolyl derivatives
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080971A1 Composition comprising an androgen receptor blocker and an insulin sensitizing agent and use thereof for treatment of polycystic ovary syndrome
10/17/2002	WO2002080955A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	WO2002080930A1 Intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with abnormal concentrations of such hormones in man and animals
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002066477A3 Imidazopyridines
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2001098354A3 Human receptors
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151557 CRF receptor antagonists and methods relating thereto
10/17/2002	US20020151551 Use of growth hormone secretagogues in conjunction with physical exercise cross reference to related application
10/17/2002	US20020151530 Administering to a woman, undergoing estrogen replacement therapy for treating homonal deficiences, continuously and uninterruptedly, a therapeutic effective amount of both estrogen and a non-aromatizing androgen in daily dosage
10/17/2002	US20020151501 Compounds having growth hormone releasing activity
10/17/2002	US20020151496 Treatment of spinal cord damage, spinal cord trauma, neuronal tissue damage produced by ischemic attack
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	CA2443085A1 Somatostatin agonists
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2441538A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/16/2002	EP1248795A1 Antisense modulation of macrophage migration inhibitory factor expression
10/16/2002	EP1248784A1 Condensed azepines as vasopressin agonists
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248637A1 Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity
10/16/2002	EP1248633A1 Antisense modulation of glycogen synthase kinase 3 beta expression
10/16/2002	EP1248626A2 Pharmaceutical compositions containing steroidal structures and uses thereof
10/16/2002	EP1248552A1 Pp14 fusion proteins and methods for making and using the same
10/16/2002	EP1248517A2 Clonal propagation of primate offspring by embryo splitting
10/16/2002	EP0868429B1 Oligopeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
10/16/2002	CN1374960A Novel integrain receptor antagonists
10/16/2002	CN1374863A Bicyclic antagonists selective for the alpha beta integrin
10/15/2002	US6465687 Thyroid receptor ligands and method
10/15/2002	US6465651 Process and intermediates for growth hormone secretagogues
10/15/2002	US6465444 Protein tyrosine phosphatases(ptp-1b); antidiabetic, antitumor and anorexigenic agents; combination therapy
10/15/2002	US6464998 Composition for the in vivo production of therapeutic products
10/15/2002	CA2038985C Haloethyl-substituted steroidal enzyme inhibitors
10/10/2002	WO2002079786A2 Method for identifying drugs for the treatment of type ii diabetes
10/10/2002	WO2002079448A2 G-protein coupled receptors
10/10/2002	WO2002079441A2 Secreted proteins
10/10/2002	WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/10/2002	WO2002079152A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002	WO2002079146A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002	WO2002078705A1 Hsp inductor
10/10/2002	WO2002078682A2 Estrogen replacement therapy
10/10/2002	WO2002078677A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer
10/10/2002	WO2002078643A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002	WO2002051390A3 Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
10/10/2002	WO2002051386A3 Lipid microparticles by cryogenic micronization
10/10/2002	WO2002046373A8 Method of collecting placental stem cells
10/10/2002	WO2002004612A3 Drug metabolizing enzymes
10/10/2002	WO2001098353A3 Secreted proteins
10/10/2002	WO2001077174A3 Human transporters and ion channels
10/10/2002	US20020147231 Allosteric adenosine receptor modulators
10/10/2002	US20020147192 Viricides; antiinflammatory agents; antiallergens; antiarthritic agents
10/10/2002	US20020147185 Antihypoxic agents, antiischamic agents, antiarrhythmia agents
10/10/2002	US20020146678 Determining preferential gene expression pattern in embryonic cells; obtain cells, monitor gene expresion products, incubate with animal growth regulators, monitor gene expresion pattern and differentiation in cells
10/10/2002	US20020146469 Administering a sensory regimen which reduces or down-regulates the activity of the hypothalamus-pituitary-adrenal (HPA) axis
10/10/2002	DE10117441A1 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate 1-indolyl derivatives, to their use for the preparation of medicaments, a process for preparing the 1-indolyl and 1-indolyl derivatives containing preparations pharmzeutische

1 ... 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 ... 290